1781From a Dosho-machi drug dealer to a drug maker
Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports & corporate yearbooks
1781The first Takeda Chobei opens a drug-dealing house on Osaka’s Dosho-machi
1871Adds the importing of Western medicines
1915Opens its own works — from mover of drugs to maker of drugs
1925Incorporated as Takeda Chobei Shoten
1943Renamed Takeda Pharmaceutical
Takeda began in June 1781, when the first Takeda Chobei took over a guild share on Dosho-machi, the Osaka street where medicine dealers traded on mutual credit, and set up as a wholesaler broking Chinese and Japanese herbal drugs to the apothecaries. On Dosho-machi trust was the whole business, and it could only be built over years of dealing; the family’s custom of passing the name “Takeda Chobei” down the generations was a device for handing that time-earned credit — the shop’s standing, not a single man’s — to the next head. In 1871 the house added the importing of Western medicines, laying a second trade over the first and acquiring, early, a habit it would never lose: when the environment shifted, abandon the old model and move upstream.
The decisive shift came with the First World War. High prices and counterfeits had already pushed Takeda to make some of its own drugs — its first dedicated factory dates to 1895 — but when the war cut off imports from Germany in 1914, the whole import-dependent structure gave way. In 1915 Takeda opened its own works in Osaka and turned, in earnest, from a firm that moved medicines into one that made them. Around this pivot it built the apparatus of a research-driven maker: a test-and-research department in 1908 (the seed of its laboratories), incorporation as Takeda Chobei Shoten in 1925, and, over the late 1930s, the domestic synthesis of vitamins C, B1 and K.
In August 1943 the firm took its present name, Takeda Pharmaceutical. The war years and the chaos that followed were anything but smooth, but Takeda came through with its plant intact — and used it well. Making vitamin and glucose preparations from whatever raw materials it could get and supplying them to the public through legitimate channels rather than the black market did as much for its reputation as any product had, and set the base for the new-drug work of the postwar decades.
1954Alinamin launched — a mass-market vitamin tonic
1959Begins selling a clioquinol preparation (later the SMON injuries)
1974Shinbei Konishi becomes president
1977SMON provisions begin; R&D spending stepped up
In March 1954 Takeda launched Alinamin, an over-the-counter tonic built on a vitamin-B1 derivative, into a malnourished postwar Japan. Advertising fronted by the film star Toshiro Mifune and a nationwide single-price system run through the “Takeda-kai” dealer network gave Takeda both a household name and control of its own distribution; by fiscal 1955 vitamin products were 37% of sales. Takeda was now a company that not only made drugs but sold them — and the mass-market model threw off cash and fame in equal measure.
It also carried a cost that would take years to surface. Leaning on a single blockbuster consumer product slowed Takeda’s investment in the prescription drugs that were becoming the industry’s real frontier; when the medicine boom broke in 1964, demand stalled and the dependence on one product bit straight into earnings. The success of Alinamin shaped Takeda’s thinking for a generation.
The same decades brought the counter-lesson. Takeda had begun selling a clioquinol preparation in 1959, and in the 1970s the SMON drug-injury scandal surfaced as a national issue. From 1977 to 1980 Takeda booked provisions totalling some $87M (¥20bn), choosing to absorb the near-term hit in order to fix the liability, shrink the uncertainty of future compensation and clear the ground for the research spending the next era would demand — spending the mass-market cash pile now made possible.
1993Kunio Takeda becomes president; “selection and concentration” begins
2008Acquires Millennium (~$8.9bn) — the North American discovery base
2011Acquires Nycomed — Europe and emerging markets
2015Christophe Weber becomes CEO — the first foreign chief
A 1976 substance-patent regime gave discovery patents real force, and Takeda pushed its R&D budget to roughly double its rivals’. Kunio Takeda, then posted to the U.S. subsidiary, concentrated resources on the prostate-cancer drug Leuprin, launched in America in 1989; its infrequent dosing won over clinicians and it grew into a mainstay earning more than $724.7M (¥100bn) worldwide. Yet nobody had aimed at a ¥100-billion drug from the start — at launch even the development director called the market “not, unfortunately, a large one” — and much of the win rested on judgment in the field and on luck. The habit of marketing it in the United States by Takeda’s own hand left inside the company the clinical and commercial base that later acquisitions would build on.
When Kunio Takeda took the presidency in 1993, he turned a diversified conglomerate back into a drug company. A 1995 plan cut 3,500 jobs toward a 7,500-person workforce, and from 2005 Takeda hived off urethane, vitamins, agrochemicals, food and life-environment businesses one by one. “We either somehow survive as a local company, or we vanish,” he said in 1996 — a blunt statement of why focus was not optional. It was the end of the long postwar diversification, and the shedding of weight Takeda needed to live on drugs alone.
Focus then exposed a thin pipeline. Under president Yasuchika Hasegawa, Takeda bought the North American cancer-discovery house Millennium for about $8.9 billion in 2008 — the start of a “buy time” strategy — and in 2011 acquired Nycomed for some $13.8B (¥1.1tn), taking Europe and the emerging markets in a single stroke. Paid for in cash, the deals avoided dilution but ended Takeda’s debt-free era and opened the door to leverage. Behind them lay the problem they were meant to solve: over the nine and a half years to late 2012, Takeda had spent roughly $30.1B (¥2.4tn) on R&D without producing a blockbuster to rival Actos. Unable to grow enough managers to run what it had bought, in 2015 it installed a foreign chief executive, Christophe Weber from GlaxoSmithKline — global logic and the admission of a succession it had not cultivated at home.
2017Acquires ARIAD; sells Wako Pure Chemical to Fujifilm
2018Global HQ opens in Tokyo; New York ADR listing
2019Acquires Shire for ~$62bn — into the global top ten
2020Sells the Alinamin OTC business to Blackstone
2026Julie Kim becomes CEO
Weber kept building by purchase — ARIAD for $5.2B (¥583bn) in 2017 to reinforce rare disease, a global headquarters opened in Tokyo in 2018 alongside the registered Osaka head office, and a New York ADR listing that December — and then made the whole strategy’s capstone bet. In January 2019 Takeda acquired Shire for roughly $62 billion, vaulting into the world’s top ten: it took a rare-disease and plasma-derived business in one move, and revenue leapt from about $18.1B (¥2tn) to past $27.5B (¥3tn). It was among the largest overseas acquisitions ever made by a Japanese company — the summing-up of the focus-then-expand strategy, and a wager pushed to the edge of Takeda’s financial capacity.
Recovering the premium took longer than planned, and interest-bearing debt swelled to about $89.9B (¥9.8tn). Weber cast Takeda, a 240-year-old house, as a company to be judged over the long term, and justified the investment on that horizon; but with goodwill charges running on, the case for a ¥6-trillion-plus outlay could only be settled by clinical results years out, and the ratings faced downgrade pressure from the day the deal closed. From then on Takeda had to carry two outflows at once — repaying the acquisition debt and funding the research that would produce the next mainstay — and reconciling the two became the axis of how it was run. By fiscal 2026 the debt had been brought back toward $28.5B (¥4.5tn).
To rebuild the balance sheet, Takeda sold Wako Pure Chemical to Fujifilm in 2017 and, in August 2020, let go of the Alinamin over-the-counter business for about $2.3B (¥250bn) to a U.S. fund — cutting loose the flagship it had sold since 1954 and closing the seventy-year model of earning cash from consumer drugs. Takeda was now, in name and in fact, a prescription-only company: a family firm that had carried a name and its credit down from an eighteenth-century drug dealer had become a foreign-led global drugmaker. In June 2026 Julie Kim succeeded Weber as CEO — the first leadership change in eleven years — inheriting a company that must now prove it can raise its next flagship in-house, launching FRUZAQLA and the dengue vaccine QDENGA from the pipeline it assembled by acquisition, all while a progressive dividend keeps shareholders on board.
The path concentration opened, and the weakness it left
Kunio Takeda’s selection and concentration was not a single decision but a strategy that took shape over more than a decade, from his 1993 accession to the presidency to the 2007 divestment of the non-drug businesses. At its root lay a reading of the numbers: a conglomerate still carrying food and agrochemicals could not recover its swelling R&D costs from the domestic market alone. The policy of pouring resources into prescription drugs and rewarding shareholders with high value-added and high payouts bore fruit as the most profitable body in the Japanese industry, and it built the concentration of resources that the later North American push and the big overseas acquisitions would require. The weight of this decision lies in a single generation turning a diversified chemicals company back into a drug specialist.
Concentration, though, threw another weakness into relief. The more Takeda cut non-drug lines and narrowed onto prescription medicines, the more its fortunes rode on the depth of its own new-drug pipeline. It had not, in fact, been generating its mainstays — Leuprin, Takepron — to a plan; part of the success rested on judgment in the field and on chance. The choice of where to place the cash earned at home — on drugs — would in time lead to the “buy time” M&A line that ran from Hasegawa’s Millennium purchase to Weber’s Shire deal. Deciding what to abandon, selection and concentration left its successors the next question: what to grow at home.
The heart of this decision was the switch from a half-committed joint venture to holding the U.S. prescription-drug business outright. Unwinding TAP brought the American sales organization inside Takeda; acquiring Millennium brought in a cancer-discovery research base. The resources Kunio Takeda had concentrated by narrowing to drugs, Hasegawa now turned toward acquiring discovery capability abroad. In this year the policy of converting profit earned at home into an operating base in the United States hardened into fact.
Buying time by buying, though, came at a price. The chain of large acquisitions that began with Millennium ran on to Nycomed and Shire; the business base widened, but lifting corporate value to match the capital deployed proved anything but easy, interest-bearing debt swelled, and the reckoning reached as far as the sale of Alinamin, the mass-market brand that had been Takeda’s signboard since the founding era. How far Takeda could grow the power to originate new drugs inside itself — the 2008 choice to own its own business in North America left that question standing over the company’s management.
The core of the Nycomed deal was that Takeda covered the sales it was losing to patent expiry not by building over several years of its own effort, but by buying a finished distribution network for more than $12.5B (¥1tn). Hasegawa overrode the caution of the board and added borrowing to what had been an essentially debt-free balance sheet, in order to spread the business into the emerging markets and Europe at a stroke. The number of countries Takeda operated in went from 28 to more than 70, and the original aim — shoring up a weak point — was indeed achieved.
Yet widening the business base and raising corporate value did not necessarily coincide. The trillion-yen-plus of capital deployed left behind a large load of goodwill and debt, which came back as later impairments, the burden of restructuring, and the country risk of Russia. Even so, the acquisition cemented in Takeda the “buy time” management begun with Millennium in 2008, and became a milestone on the road to the roughly $62 billion Shire acquisition of 2019. How to grow a bought-in, widened business into value worthy of the capital deployed — the question Nycomed posed still stands before today’s Takeda.
A succession that severed management from nationality
The heart of this decision was that, to govern a business it had spread across the world, Takeda stepped into the internationalization of management itself. It had extended its operations globally by acquisition while failing to grow, from within, the executives to bind them together. Hasegawa and the board chose not to wait on in-house development but to bring in from outside a foreigner who knew the market well. Opening a management that founding family and lifers had carried for more than two centuries into a single post held regardless of nationality is what marks the character of this succession.
Recruiting from outside, however, sped the internationalization of the business while deferring the time it would take to raise the next chief at home. The Weber regime ran to about twelve years — a long tenure not easily changed even when results stalled. That Takeda entrusted the next CEO, in 2026, to another foreigner in Julie Kim is the flip side of the same fact. The fruit of globalization, and the unmet task of growing management talent in-house — the recruitment of a foreign chief left both behind at once.
The character of this acquisition shows in the sheer size of the number. Unable to originate an Actos-class drug from its own laboratories, Takeda had since Leuprin in 1989 kept buying its business base from outside — Millennium, Nycomed, ARIAD, Shire. The roughly $62 billion price tag was less a mark of confidence in growth than the reverse of a fear: that without buying time with money, Takeda could not stay among the world’s leaders. Filling the gaps quickly by buying both businesses and people, it skipped the time to cultivate — and the cost came back in the form of letting go of Alinamin, the signboard product.
By taking Shire in, Takeda turned a family company descended from an Edo-period drug dealer into a foreign-led global drug specialist. Revenue jumped from about $18.1B (¥2tn) to past $27.5B (¥3tn), and the centre of the business moved from domestic distribution and consumer drugs to overseas rare disease and discovery. Against that, the double burden of repaying six-trillion-yen-class debt while growing the next mainstay passes straight to the management that succeeds Weber. For a company that measures its 240 years on a long ruler, whether this acquisition was an expansion or an overreach will be decided by the number of new drugs still to come.
The price of buying scale and selling the flagship
The core of this sale was that it met two aims — repairing the finances and narrowing the business — in one transaction. Having grown to the world’s top ten through the Shire acquisition, Takeda carried heavy debt as the price, and looked to non-core divestments for the means to repay it. That what was sold was Alinamin, the signboard product since the founding era, mirrors the underside of scaling up: compressing, with acquisition-swollen debt, the very business the acquisitions had widened. The selection and concentration that Kunio Takeda began a quarter-century earlier reached a punctuation mark with the letting-go of the consumer-drug business.
What remains is the question of how far a strategy that buys rather than grows can run. Rather than originate a product like Alinamin, which took long years to take root among the public, Takeda made up its scale with businesses obtained from outside — and let go of the consumer-drug earner. A structure concentrated on prescription drugs is also a wager on whether it can originate its next mainstay in-house. Alinamin, parted from the parent in 2021, can be re-read as one example of what an acquisition line that raised scale and debt together gained, and what it gave up.
Each heading links to the full Japanese analysis — background, decision and outcome, with sources.
This is a condensed English edition. The full, source-by-source history — with the detailed narrative, financial tables, shareholders and executives — is maintained in Japanese: 日本語版（詳細）— Takeda Pharmaceutical full history in Japanese →